Immutep's Efti Shows Promise in Sarcoma Trial

TipRanksMay 3 08:01 ET

Initial Clinical Data Reported From Immutep's Efti Combined With Radiotherapy And Checkpoint Inhibitor From Phase II Trial In Soft Tissue Sarcoma

Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six patients treated h

BenzingaMay 2 08:07 ET

Immutep's Innovative Cancer Therapy Shows Promise

TipRanksMay 1 20:47 ET

Immutep Started at Buy by Canaccord Genuity >IMM.AU

Immutep Started at Buy by Canaccord Genuity >IMM.AU

Dow JonesApr 30 18:17 ET

Immutep Shares Upbeat Clinical Trials Update

TipRanksApr 30 07:29 ET

Canaccord Starts Immutep at Buy, Price Target Is AU$1.00

09:02 PM EDT, 04/29/2024 (MT Newswires) -- Canaccord Starts Immutep at Buy, Price Target is AU$1.00 Price (AUD): $0.45, Change: $, Percent Change: %

MT NewswiresApr 29 21:02 ET